지방간 치료제 시장 : 시장 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of fatty liver disease drugs Market

The global fatty liver disease drugs market was valued at USD 983.4 million in 2025. The market is projected to grow from USD 1,620.0 million in 2026 to USD 9,194.1 million by 2034, exhibiting a CAGR of 24.24% during the forecast period. The strong expansion reflects the transition of the market from a pipeline-driven stage to early commercialization, supported by increasing diagnosis rates and growing availability of approved therapies for metabolic dysfunction-associated steatohepatitis (MASH).

The market refers to pharmaceutical treatments developed for fatty liver disease, particularly MASH patients with moderate to advanced fibrosis. These therapies include oral and injectable drugs targeting metabolic pathways, inflammation, and fibrosis progression. Rising obesity rates, improved non-invasive diagnostic tools, and increasing awareness among healthcare providers are significantly driving market adoption.

Key drivers include the rising global burden of obesity and diabetes, increasing prevalence of liver fibrosis, improved disease screening, and expanding clinical adoption of newly approved therapies. Benefits such as disease modification, improved liver function, and targeted metabolic action further support market growth. Additionally, strong R&D investments and expanding drug pipelines are accelerating innovation.

Major players include Madrigal Pharmaceuticals, Novo Nordisk, Boehringer Ingelheim, Akero Therapeutics, Inventiva, Viking Therapeutics, and Altimmune, focusing on GLP-1 therapies, THR-beta agonists, and FGF21-based drug development strategies.

Market Share

North America dominated the market in 2025 due to high obesity prevalence and early access to approved therapies.

The THR-beta agonist segment held the largest share in 2025, driven by strong adoption of first approved oral MASH therapy.

The oral route of administration segment dominated due to convenience and strong physician preference.

REGIONAL OUTLOOK

North America leads the global fatty liver disease drugs market due to high disease prevalence, strong diagnostic infrastructure, and early commercialization of branded therapies. The U.S. contributes the majority share due to rapid drug adoption and strong reimbursement systems.

Europe is expected to grow significantly, supported by increasing awareness of liver diseases and expanding hepatology care pathways. Asia Pacific is projected to register the fastest growth due to a large patient population and rising metabolic disorders across China, India, and Japan. The Rest of the World is witnessing gradual adoption supported by improving healthcare access.

MARKET DRIVERS

A major driver is the rising global obesity burden, which directly increases the incidence of fatty liver disease and MASH. This expands the patient pool requiring targeted pharmaceutical intervention beyond lifestyle management.

Another key driver is improved diagnostic capability using non-invasive fibrosis detection methods. Early identification of patients has significantly increased treatment eligibility, driving demand for approved and pipeline therapies.

MARKET RESTRAINTS

High clinical trial failure rates remain a key restraint due to the complex nature of MASH, where achieving consistent treatment outcomes across fibrosis stages is challenging. This increases development costs and delays product approvals.

MARKET OPPORTUNITIES

Strong opportunities exist in combination therapies and pipeline expansion through strategic collaborations. Partnerships between pharmaceutical companies are accelerating drug development and expanding treatment options across different disease stages, improving commercial potential.

MARKET CHALLENGES

Regulatory uncertainty is a major challenge as approval requirements for fibrosis improvement and long-term outcomes continue to evolve. This increases development timelines and complicates global commercialization strategies.

SEGMENTATION ANALYSIS

By Product

Rezdiffra (resmetirom) dominates the market as the first approved MASH-specific therapy with strong early commercial uptake. Wegovy (semaglutide) is the fastest-growing segment due to expanding metabolic and obesity-related applications.

By Drug Class

THR-beta agonists lead the market due to liver-specific mechanisms and strong clinical validation. GLP-1 receptor agonists are the fastest growing due to their dual benefits in obesity and metabolic regulation.

By Route of Administration

The oral segment dominates due to convenience, better patient compliance, and ease of long-term use. The parenteral segment is growing rapidly due to advanced injectable biologics in development pipelines.

By Distribution Channel

Specialty pharmacies dominate due to the need for prior authorization, reimbursement support, and patient management programs. Retail pharmacies are growing steadily with broader drug availability.

COMPETITIVE LANDSCAPE

The market is moderately consolidated, with Madrigal Pharmaceuticals leading due to early approval and strong commercial rollout of Rezdiffra. Novo Nordisk is strengthening its position through GLP-1 based therapies, while other players are focusing on pipeline expansion and strategic partnerships. Competition is intensifying as multiple late-stage candidates move toward commercialization.

LIST OF KEY COMPANIES

Madrigal Pharmaceuticals, Inc.

Novo Nordisk

Boehringer Ingelheim International GmbH

Inventiva

Viking Therapeutics

Altimmune

Akero Therapeutics

89bio (F. Hoffmann-La Roche Ltd)

INDUSTRY DEVELOPMENTS

2026: Altimmune received FDA Breakthrough Therapy Designation for pemvidutide in MASH.

2026: EMA CHMP issued positive opinion for semaglutide in non-cirrhotic MASH.

2025: Roche acquired 89bio to strengthen its MASH pipeline.

2025: Madrigal expanded global licensing agreements for oral GLP-1 assets.

2025: Altimmune reported positive Phase 2b MASH clinical results.

CONCLUSION

The global fatty liver disease drugs market is expected to grow rapidly from USD 983.4 million in 2025 to USD 1,620.0 million in 2026 and reach USD 9,194.1 million by 2034. The market growth is driven by rising obesity prevalence, increasing diagnosis of MASH, and rapid commercialization of new drug therapies. Strong pipeline development, expanding approvals, and strategic collaborations are further strengthening long-term growth prospects. With increasing clinical adoption and innovation in metabolic and liver-targeted therapies, the market is expected to witness strong and sustained expansion throughout the forecast period.

Segmentation By Product, Drug Class, Route of Administration, Distribution Channel, and Region

By Product * Rezdiffra (Resmetirom)

• Wegovy (Semaglutide)
• Others

By Drug Class * THR-beta Agonist

• GLP-1 Receptor Agonist
• Others

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital Pharmacies

• Retail Pharmacies & Drug Stores
• Specialty Pharmacies & Others

By Region * North America (By Product, Drug Class, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Product, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Product, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Rest of the World (By Product, Drug Class, Route of Administration, and Distribution Channel)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Pipeline Analysis, By Key Players
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.3. New Product Launches, By Key Players
• 4.4. Regulatory Scenario, By Key Countries/Regions

5. Global Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Rezdiffra (Resmetirom)
  • 5.1.2. Wegovy (Semaglutide)
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. THR-beta Agonist
  • 5.2.2. GLP-1 Receptor Agonist
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Parenteral
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies & Drug Stores
  • 5.4.3. Specialty Pharmacies & Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Rest of the World

6. North America Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Rezdiffra (Resmetirom)
  • 6.1.2. Wegovy (Semaglutide)
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. THR-beta Agonist
  • 6.2.2. GLP-1 Receptor Agonist
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Parenteral
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies & Drug Stores
  • 6.4.3. Specialty Pharmacies & Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Rezdiffra (Resmetirom)
  • 7.1.2. Wegovy (Semaglutide)
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. THR-beta Agonist
  • 7.2.2. GLP-1 Receptor Agonist
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Parenteral
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies & Drug Stores
  • 7.4.3. Specialty Pharmacies & Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Rest of Europe

8. Asia Pacific Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Rezdiffra (Resmetirom)
  • 8.1.2. Wegovy (Semaglutide)
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. THR-beta Agonist
  • 8.2.2. GLP-1 Receptor Agonist
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Parenteral
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies & Drug Stores
  • 8.4.3. Specialty Pharmacies & Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Rest of Asia Pacific

9. Rest of the World Fatty Liver Disease Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Rezdiffra (Resmetirom)
  • 9.1.2. Wegovy (Semaglutide)
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. THR-beta Agonist
  • 9.2.2. GLP-1 Receptor Agonist
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Parenteral
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies & Drug Stores
  • 9.4.3. Specialty Pharmacies & Others

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Madrigal Pharmaceuticals, Inc.
  • 10.2.2. Novo Nordisk
  • 10.2.3. F. Hoffmann-La Roche Ltd (89bio, Inc.)
  • 10.2.4. Inventiva
  • 10.2.5. Boehringer Ingelheim International GmbH
  • 10.2.6. Viking Therapeutics
  • 10.2.7. Altimmune